Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 94

1.

Deferred treatment with a fixed-dose combination of sofosbuvir-velpatasvir for chronic hepatitis C virus genotype 1, 2, 4 and 6 infection.

Asselah T, Shafran SD, Bourgeois S, Lai CL, Mathurin P, Willems B, Nguyen MH, Davis MN, Huang KC, Svarovskaia E, Osinusi A, McNally J, Brainard DM, Shaikh OS, Tran TT.

J Viral Hepat. 2019 Oct;26(10):1229-1232. doi: 10.1111/jvh.13159. Epub 2019 Aug 4.

PMID:
31216086
2.

Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis.

Borgia SM, Dearden J, Yoshida EM, Shafran SD, Brown A, Ben-Ari Z, Cramp ME, Cooper C, Foxton M, Rodriguez CF, Esteban R, Hyland R, Lu S, Kirby BJ, Meng A, Markova S, Dvory-Sobol H, Osinusi AO, Bruck R, Ampuero J, Ryder SD, Agarwal K, Fox R, Shaw D, Haider S, Willems B, Lurie Y, Calleja JL, Gane EJ.

J Hepatol. 2019 Oct;71(4):660-665. doi: 10.1016/j.jhep.2019.05.028. Epub 2019 Jun 11.

3.

Planning HIV therapy to prevent future comorbidities: patient years for tenofovir alafenamide.

Shafran SD, Di Perri G, Esser S, Lelièvre JD, Parczewski M.

HIV Med. 2019 Jun;20 Suppl 7:1-16. doi: 10.1111/hiv.12755. Review.

PMID:
31099116
4.

Identification of 19 Novel Hepatitis C Virus Subtypes-Further Expanding HCV Classification.

Hedskog C, Parhy B, Chang S, Zeuzem S, Moreno C, Shafran SD, Borgia SM, Asselah T, Alric L, Abergel A, Chen JJ, Collier J, Kapoor D, Hyland RH, Simmonds P, Mo H, Svarovskaia ES.

Open Forum Infect Dis. 2019 Feb 22;6(3):ofz076. doi: 10.1093/ofid/ofz076. eCollection 2019 Mar.

5.

Prevention of Shingles: Better Protection and Better Value With Recombinant Vaccine.

Shafran SD.

Ann Intern Med. 2019 Mar 19;170(6):416-417. doi: 10.7326/M19-0141. Epub 2019 Feb 19. No abstract available.

PMID:
30776802
6.

Daclatasvir and sofosbuvir with ribavirin for 24 weeks in chronic hepatitis C genotype-3-infected patients with cirrhosis: a Phase III study (ALLY-3C).

Poordad F, Shiffman ML, Ghesquiere W, Wong A, Huhn GD, Wong F, Ramji A, Shafran SD, McPhee F, Yang R, Noviello S, Linaberry M; ALLY-3C study team.

Antivir Ther. 2019;24(1):35-44. doi: 10.3851/IMP3278.

PMID:
30382942
7.

Identification of a Novel Hepatitis C Virus Genotype From Punjab, India: Expanding Classification of Hepatitis C Virus Into 8 Genotypes.

Borgia SM, Hedskog C, Parhy B, Hyland RH, Stamm LM, Brainard DM, Subramanian MG, McHutchison JG, Mo H, Svarovskaia E, Shafran SD.

J Infect Dis. 2018 Oct 20;218(11):1722-1729. doi: 10.1093/infdis/jiy401.

PMID:
29982508
8.

Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies.

Hezode C, Reau N, Svarovskaia ES, Doehle BP, Shanmugam R, Dvory-Sobol H, Hedskog C, McNally J, Osinusi A, Brainard DM, Miller MD, Mo H, Roberts SK, O'Leary JG, Shafran SD, Zeuzem S.

J Hepatol. 2018 May;68(5):895-903. doi: 10.1016/j.jhep.2017.11.032. Epub 2017 Dec 6.

PMID:
29221887
9.

Efficacy and safety results of patients with HCV genotype 2 or 3 infection treated with ombitasvir/paritaprevir/ritonavir and sofosbuvir with or without ribavirin (QUARTZ II-III).

Shafran SD, Shaw D, Charafeddine M, Agarwal K, Foster GR, Abunimeh M, Pilot-Matias T, Pothacamury RK, Fu B, Cohen E, Cohen DE, Gane E.

J Viral Hepat. 2018 Feb;25(2):118-125. doi: 10.1111/jvh.12782. Epub 2017 Sep 14.

PMID:
28833938
10.

Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label Study.

Feld JJ, Ramji A, Shafran SD, Willems B, Marotta P, Huchet E, Vachon ML, Svarovskaia ES, Huang KC, Hyland RH, Yun C, Massetto B, Brainard DM, McHutchison JG, Tam E, Bailey R, Cooper C, Yoshida EM, Greenbloom S, Elkhashab M, Borgia S, Swain MG.

Clin Infect Dis. 2017 Jul 1;65(1):13-19. doi: 10.1093/cid/cix289.

PMID:
28535298
11.

Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials.

Jacobson IM, Lawitz E, Gane EJ, Willems BE, Ruane PJ, Nahass RG, Borgia SM, Shafran SD, Workowski KA, Pearlman B, Hyland RH, Stamm LM, Svarovskaia E, Dvory-Sobol H, Zhu Y, Subramanian GM, Brainard DM, McHutchison JG, Bräu N, Berg T, Agarwal K, Bhandari BR, Davis M, Feld JJ, Dore GJ, Stedman CAM, Thompson AJ, Asselah T, Roberts SK, Foster GR.

Gastroenterology. 2017 Jul;153(1):113-122. doi: 10.1053/j.gastro.2017.03.047. Epub 2017 Apr 5.

PMID:
28390869
12.

Response to: Comment on "Hepatitis C and the Sex Trade".

Shafran SD.

Can J Gastroenterol Hepatol. 2016;2016:5474217. doi: 10.1155/2016/5474217. Epub 2016 Jun 28. No abstract available.

13.

Reply to Menard et al.

Shafran SD.

Clin Infect Dis. 2016 Apr 1;62(7):949-50. doi: 10.1093/cid/civ1217. Epub 2016 Jan 5. No abstract available.

PMID:
26740516
14.

Hepatitis C and the sex trade.

Shafran SD.

Can J Gastroenterol Hepatol. 2015 Nov-Dec;29(8):405-6. No abstract available.

15.

Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection.

Feld JJ, Jacobson IM, Hézode C, Asselah T, Ruane PJ, Gruener N, Abergel A, Mangia A, Lai CL, Chan HL, Mazzotta F, Moreno C, Yoshida E, Shafran SD, Towner WJ, Tran TT, McNally J, Osinusi A, Svarovskaia E, Zhu Y, Brainard DM, McHutchison JG, Agarwal K, Zeuzem S; ASTRAL-1 Investigators.

N Engl J Med. 2015 Dec 31;373(27):2599-607. doi: 10.1056/NEJMoa1512610. Epub 2015 Nov 16.

16.

Live attenuated herpes zoster vaccine for HIV-infected adults.

Shafran SD.

HIV Med. 2016 Apr;17(4):305-10. doi: 10.1111/hiv.12311. Epub 2015 Aug 27.

17.

Extended treatment with pegylated interferon alfa/ribavirin in patients with genotype 2/3 chronic hepatitis C who do not achieve a rapid virological response: final analysis of the randomised N-CORE trial.

Shiffman ML, Cheinquer H, Berg CP, Berg T, de Figueiredo-Mendes C, Dore GJ, Ferraz ML, Mendes-Corrêa MC, Lima MP, Parise ER, Rios AM, Reuter T, Sanyal AJ, Shafran SD, Hohmann M, Tatsch F, Bakalos G, Zeuzem S.

Hepatol Int. 2014 Oct;8(4):517-26. doi: 10.1007/s12072-014-9555-3. Epub 2014 Jul 24.

PMID:
26202757
18.

HIV Coinfected Have Similar SVR Rates as HCV Monoinfected With DAAs: It's Time to End Segregation and Integrate HIV Patients Into HCV Trials.

Shafran SD.

Clin Infect Dis. 2015 Oct 1;61(7):1127-34. doi: 10.1093/cid/civ438. Epub 2015 Jun 9.

PMID:
26060286
19.
20.

Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection.

Dore GJ, Lawitz E, Hézode C, Shafran SD, Ramji A, Tatum HA, Taliani G, Tran A, Brunetto MR, Zaltron S, Strasser SI, Weis N, Ghesquiere W, Lee SS, Larrey D, Pol S, Harley H, George J, Fung SK, de Lédinghen V, Hagens P, McPhee F, Hernandez D, Cohen D, Cooney E, Noviello S, Hughes EA.

Gastroenterology. 2015 Feb;148(2):355-366.e1. doi: 10.1053/j.gastro.2014.10.007. Epub 2014 Oct 13.

PMID:
25311593
21.

Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study.

Hézode C, Hirschfield GM, Ghesquiere W, Sievert W, Rodriguez-Torres M, Shafran SD, Thuluvath PJ, Tatum HA, Waked I, Esmat G, Lawitz EJ, Rustgi VK, Pol S, Weis N, Pockros PJ, Bourlière M, Serfaty L, Vierling JM, Fried MW, Weiland O, Brunetto MR, Everson GT, Zeuzem S, Kwo PY, Sulkowski M, Bräu N, Hernandez D, McPhee F, Wind-Rotolo M, Liu Z, Noviello S, Hughes EA, Yin PD, Schnittman S.

Gut. 2015 Jun;64(6):948-56. doi: 10.1136/gutjnl-2014-307498. Epub 2014 Jul 30.

PMID:
25080450
22.

Treating Clostridium difficile infection.

Shafran DM, Shafran SD.

CMAJ. 2014 Apr 15;186(7):531. doi: 10.1503/cmaj.131315. Epub 2013 Dec 16. Review. No abstract available.

23.

Seroprevalence of HSV-1 and HSV-2 antibodies in Canadian women screened for enrolment in a herpes simplex virus vaccine trial.

Gorfinkel IS, Aoki F, McNeil S, Dionne M, Shafran SD, Zickler P, Halperin S, Langley J, Bellamy A, Schulte J, Heineman T, Belshe R.

Int J STD AIDS. 2013 May;24(5):345-9. doi: 10.1177/0956462412472822.

PMID:
23970700
24.

Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial.

Sulkowski MS, Bourlière M, Bronowicki JP, Asselah T, Pawlotsky JM, Shafran SD, Pol S, Mauss S, Larrey D, Datsenko Y, Stern JO, Kukolj G, Scherer J, Nehmiz G, Steinmann GG, Böcher WO.

Hepatology. 2013 Jun;57(6):2155-63. doi: 10.1002/hep.26386.

PMID:
23504636
25.

Optimal use of raltegravir (Isentress(R)) in the treatment of HIV-infected adults - Canadian consensus guidelines.

Rachlis A, Angel JB, Harris M, Shafran SD, Therrien R, Tremblay C, Wainberg MA.

Can J Infect Dis Med Microbiol. 2009 Fall;20(3):e67-80.

26.

Challenges in initiating antiretroviral therapy in 2010.

Tremblay CL, Baril JG, Fletcher D, Kilby D, Macpherson P, Shafran SD, Tyndall MW.

Can J Infect Dis Med Microbiol. 2010 Aug;21 Suppl C:1C-15C.

27.

Canadian clinical practice guidelines for invasive candidiasis in adults.

Bow EJ, Evans G, Fuller J, Laverdière M, Rotstein C, Rennie R, Shafran SD, Sheppard D, Carle S, Phillips P, Vinh DC.

Can J Infect Dis Med Microbiol. 2010 Winter;21(4):e122-50.

28.

Canadian consensus guidelines for the optimal use of maraviroc in the treatment of HIV-infected adults.

Rachlis A, Harris M, Lalonde R, Shafran SD, Tremblay C, Wainberg MA, Walmsley S.

Can J Infect Dis Med Microbiol. 2010 Winter;21(4):159-72.

29.

Drug-drug interaction between itraconazole and the protease inhibitor lopinavir/ritonavir.

Hills-Nieminen C, Hughes CA, Houston S, Shafran SD.

Ann Pharmacother. 2009 Dec;43(12):2117-20. doi: 10.1345/aph.1M393. Epub 2009 Nov 24.

PMID:
19934385
30.

Canadian consensus guidelines for the management of cytomegalovirus disease in HIV/AIDS.

Lalonde RG, Boivin G, Deschênes J, Hodge WG, Hopkins JJ, Klein AH, Lindley JI, Phillips P, Shafran SD, Walmsley S.

Can J Infect Dis Med Microbiol. 2004 Nov;15(6):327-35.

31.

Nelfinavir and non-nucleoside reverse transcriptase inhibitor-based salvage regimens in heavily HIV pretreated patients.

Baril JG, Lefebvre EA, Lalonde RG, Shafran SD, Conway B.

Can J Infect Dis. 2003 Jul;14(4):201-5.

32.

Isolated native tricuspid valve endocarditis caused by viridans streptococcus.

Swiston J, Shafran SD, Kassam N.

Can J Infect Dis. 2001 Sep;12(5):305-7.

33.

Randomized controlled trial of once-daily tenofovir, lamivudine, and lopinavir/ritonavir versus remaining on the same regimen in virologically suppressed HIV-infected patients on their first PI-containing HAART regimen.

Loutfy MR, Ackad N, Antoniou T, Baril JG, Conway B, de Wet J, Trottier B, Kovacs CM, Thompson W, Martel AY, Trottier S, Rouleau D, Shafran SD, Rachlis A, Fraser C, Smaill F, Walmsley SL, Tseng AL, Sampalis JS.

HIV Clin Trials. 2007 Sep-Oct;8(5):259-68.

PMID:
17956827
34.

Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.

Shiffman ML, Suter F, Bacon BR, Nelson D, Harley H, Solá R, Shafran SD, Barange K, Lin A, Soman A, Zeuzem S; ACCELERATE Investigators.

N Engl J Med. 2007 Jul 12;357(2):124-34.

36.
37.

Treatment of hepatitis C in HIV-coinfected patients.

Hughes CA, Shafran SD.

Ann Pharmacother. 2006 Mar;40(3):479-89; quiz 582-3. Epub 2006 Feb 28. Review.

PMID:
16507622
38.

Chronic hepatitis C virus management: 2000-2005 update.

Hughes CA, Shafran SD.

Ann Pharmacother. 2006 Jan;40(1):74-82. Epub 2005 Dec 20. Review.

PMID:
16368925
39.

The effect of low-dose ritonavir monotherapy on fasting serum lipid concentrations.

Shafran SD, Mashinter LD, Roberts SE.

HIV Med. 2005 Nov;6(6):421-5.

40.

Clinic-initiated, twice-daily oral famciclovir for treatment of recurrent genital herpes: a randomized, double-blind, controlled trial.

Sacks SL, Aoki FY, Martel AY, Shafran SD, Lassonde M.

Clin Infect Dis. 2005 Oct 15;41(8):1097-104. Epub 2005 Sep 12.

PMID:
16163627
41.

Oral famciclovir for the suppression of recurrent genital herpes: the combined data from two randomized controlled trials.

Tyring SK, Diaz-Mitoma F, Shafran SD, Locke LA, Sacks SL, Young CL.

J Cutan Med Surg. 2003 Nov-Dec;7(6):449-54.

PMID:
15931690
42.

Safety and immunogenicity of glycoprotein D-adjuvant genital herpes vaccine.

Bernstein DI, Aoki FY, Tyring SK, Stanberry LR, St-Pierre C, Shafran SD, Leroux-Roels G, Van Herck K, Bollaerts A, Dubin G; GlaxoSmithKline Herpes Vaccine Study Group.

Clin Infect Dis. 2005 May 1;40(9):1271-81. Epub 2005 Mar 24.

PMID:
15825029
43.

The effect of current management on morbidity and mortality in hospitalised adults with funguria.

Simpson C, Blitz S, Shafran SD.

J Infect. 2004 Oct;49(3):248-52.

PMID:
15337343
44.

Once, twice, or three times daily famciclovir compared with aciclovir for the oral treatment of herpes zoster in immunocompetent adults: a randomized, multicenter, double-blind clinical trial.

Shafran SD, Tyring SK, Ashton R, Decroix J, Forszpaniak C, Wade A, Paulet C, Candaele D.

J Clin Virol. 2004 Apr;29(4):248-53.

PMID:
15018852
45.

Dexamethasone improved disability in acute bacterial meningitis.

Shafran SD.

ACP J Club. 2003 May-Jun;138(3):60. No abstract available.

PMID:
12725615
46.

Analysis of Mycobacterium avium complex isolates from blood samples of AIDS patients by pulsed-field gel electrophoresis.

Kunimoto DY, Peppler MS, Talbot J, Phillips P, Shafran SD; Canadian HIV Trials Network Protocol 010 Study Group.

J Clin Microbiol. 2003 Jan;41(1):498-9.

47.

Successful discontinuation of therapy for disseminated Mycobacterium avium complex infection after effective antiretroviral therapy.

Shafran SD, Mashinter LD, Phillips P, Lalonde RG, Gill MJ, Walmsley SL, Toma E, Conway B, Fong IW, Rachlis AR, Williams KE, Garber GE, Schlech WF, Smaill F, Pradier C.

Ann Intern Med. 2002 Nov 5;137(9):734-7.

PMID:
12416943
48.

Infective endocarditis and perivalvular abscess: a dangerous duo.

Shafran SD.

CMAJ. 2002 Jul 9;167(1):38-9. No abstract available.

49.

Field evaluation of the Merlin immediate HIV-1 and -2 test for point-of-care detection of human immunodeficiency virus antibodies.

Shafran SD, Conway B, Prasad E, Greer J, Vincelette J, Ellis CE, Haase DA, Walmsley SL, Lalonde RG, Cameron DW.

Clin Infect Dis. 2002 Mar 1;34(5):658-61. Epub 2002 Jan 25.

PMID:
11823955
50.

Acute bacterial meningitis in adults. A 12-year review.

Hussein AS, Shafran SD.

Medicine (Baltimore). 2000 Nov;79(6):360-8. Review.

Supplemental Content

Loading ...
Support Center